Literature DB >> 11602672

Protein kinase C-epsilon is a trigger of delayed cardioprotection against myocardial ischemia of kappa-opioid receptor stimulation in rat ventricular myocytes.

G Y Wang1, J J Zhou, J Shan, T M Wong.   

Abstract

Kappa-opioid receptor (OR) stimulation with a selective agonist, U50,488H (U50), known to mediate the delayed cardioprotection of metabolic inhibition preconditioning (MIP) against cell injury/death in rat ventricular myocytes, has been shown to act via protein kinase C (PKC). We attempted to identify the PKC isoform(s) that is activated, thus triggering delayed cardioprotection of MIP and pretreatment with 10 microM U50 (U50 pretreatment, UP). Release of lactate dehydrogenase and exclusion of trypan blue by isolated rat ventricular myocytes were used as indices of cell injury and death, respectively. Both MIP and UP induced translocation of PKC-epsilon, but not other PKC isoforms, -alpha and -delta, from cytosolic to membrane fractions. This was accompanied by reductions in cell injury/death induced by lethal simulated ischemia. The effects of MIP and UP were attenuated and abolished by 1 microM nor-binaltorphimine, a selective kappa-OR antagonist, administered before and during preconditioning/pretreatment, respectively. The effects were mimicked by 10 nM phorbol-12-myristate-13-acetate, a PKC activator, but attenuated by 5 microM chelerythrine, a PKC inhibitor. More importantly, 0.1 microM epsilonV1-2, a selective PKC-epsilon inhibitor administered before and during MIP/UP, also attenuated the effects of both treatments on cell injury/death and translocation of PKC-epsilon. On the other hand, 5 microM rottlerin, a selective PKC-delta inhibitor, did not alter the effects of either treatment on injury/death. The results indicate that both MIP and UP activate PKC-epsilon, leading to delayed cardioprotection in rat ventricular myocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602672

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Sevoflurane-induced delayed neuroprotection involves mitoK(ATP) channel opening and PKC ε activation.

Authors:  Zhi Ye; Yue-Ming Huang; E Wang; Zhi-Yi Zuo; Qu-Lian Guo
Journal:  Mol Biol Rep       Date:  2012-03-04       Impact factor: 2.316

2.  Role of protein kinase C-epsilon in the development of kappa-opioid receptor tolerance to U50,488H in rat ventricular myocytes.

Authors:  Jing-Jun Zhou; Jin-Song Bian; Jian-Ming Pei; Song Wu; Hong-Yu Li; Tak-Ming Wong
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

3.  The K(Ca) channel as a trigger for the cardioprotection induced by kappa-opioid receptor stimulation -- its relationship with protein kinase C.

Authors:  Chun-Mei Cao; Mai Chen; Tak-Ming Wong
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

4.  Failure to confer cardioprotection and to increase the expression of heat-shock protein 70 by preconditioning with a kappa-opioid receptor agonist during ischaemia and reperfusion in streptozotocin-induced diabetic rats.

Authors:  J S Qi; K W L Kam; M Chen; S Wu; T M Wong
Journal:  Diabetologia       Date:  2004-01-09       Impact factor: 10.122

5.  Roles of KATP channels in delayed cardioprotection and intracellular Ca(2+) in the rat heart as revealed by kappa-opioid receptor stimulation with U50488H.

Authors:  Mai Chen; Jing-Jun Zhou; Kenneth Wan-Lung Kam; Jian-Song Qi; Wing-Yi Yan; Song Wu; Tak-Ming Wong
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

Review 6.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

Review 7.  Protein Kinases as Drug Development Targets for Heart Disease Therapy.

Authors:  Naranjan S Dhalla; Alison L Müller
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-05

8.  l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway.

Authors:  Olivia J Robertson-Gray; Sarah K Walsh; Erik Ryberg; Ann-Cathrine Jönsson-Rylander; Christopher Lipina; Cherry L Wainwright
Journal:  Pharmacol Res Perspect       Date:  2019-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.